• Title/Summary/Keyword: Lung, neoplasms

Search Result 372, Processing Time 0.023 seconds

Druggable Targets of Squamous Cell Lung Cancer

  • Kim, Cheol Hyeon
    • Tuberculosis and Respiratory Diseases
    • /
    • v.75 no.6
    • /
    • pp.231-235
    • /
    • 2013
  • Knowledge of molecular pathogenesis of non-small cell lung cancer has increased remarkably and changed the principles of treatment, especially during the past decade. These advancements have been limited mainly to adenocarcinoma of the lung. Recently, genetic alterations in squamous cell lung cancer (SQCLC) have been detailed and positive results of clinical trials using agents targeting these changes have indicated the potential for improved treatment outcomes for SQCLC.

Year-in-Review of Lung Cancer

  • Son, Ji Woong
    • Tuberculosis and Respiratory Diseases
    • /
    • v.73 no.3
    • /
    • pp.137-142
    • /
    • 2012
  • In the last several years, we have made slow but steady progress in understanding molecular biology of lung cancer. This review is focused on advances in understanding the biology of lung cancer that have led to proof of concept studies on new therapeutic approaches. The three selected topics include genetics, epigenetics and non-coding RNA. This new information represents progress in the integration of molecular mechanisms that to identify more effective ways to target lung cancer.

Video-Assisted Thoracic Surgery Mediastinal Lymph Node Dissection in Lung Cancer Surgery

  • Kim, Kwhanmien
    • Journal of Chest Surgery
    • /
    • v.54 no.4
    • /
    • pp.258-262
    • /
    • 2021
  • Mediastinal lymph node dissection is an important part of lung cancer surgery that provides accurate nodal staging and may improve survival outcomes. The minimally invasive approach, such as video-assisted thoracic surgery (VATS) lobectomy for patients with non-small cell lung cancer, has become a standard operation worldwide. VATS mediastinal lymph node dissection should be thorough and accurate to ensure the completeness of lung cancer surgery. Herein, the author describes techniques for VATS mediastinal lymph node dissection.

RVOTO Caused by Pulmonary Artery Sarcoma Originating from Pulmonary Valve -Two case report- (식도와 폐의 동시성 중복암 -2예 보고 -)

  • 김대현;이인호;윤효철;김수철;김범식;조규석;박주철
    • Journal of Chest Surgery
    • /
    • v.37 no.2
    • /
    • pp.184-187
    • /
    • 2004
  • The synchronous double cancer of the esophagus and lung is rare. Right lower lobectomy and Ivor Lewis procedure were performed simultaneously in a 75 year-old male patient who had synchronous double primary squamous cell carcinoma of the thoracic esophagus and right lower lobe of the lung, Left upper lobectomy was performed in a 69 year-old male patient who had squamous cell carcinoma of the left upper lobe of the lung, and four months later we performed Ivor Lewis procedure for the squamous cell carcinoma that occurred in the thoracic esophagus. The above two patients were doing well 10 months and 24 months after the operation respectively without recurrence. We treated the two cases of synchronous double cancer of the esophagus and lung with complete resection, and report this with review of literature.

Malignant Fibrous histiocytoma of the Lung - A case report - (폐에 발생한 악성 섬유 조직구종 1례 보)

  • 나석주
    • Journal of Chest Surgery
    • /
    • v.20 no.3
    • /
    • pp.598-602
    • /
    • 1987
  • Primary sarcomas of the lung are rare malignant neoplasms which have usually been classified as fibrosarcomas or leiomyosarcomas. Only 10 cases of primary malignant fibrous histiocytoma [MFH] of the lung have previously been reported in the literatures. The histomorphology of the MFH is marked by their extensive cellular variability, nuclear atypia, abnormal mitotic figures and storiform arrangement of the cells. Recently, we experienced a case of MFH, arising in the parenchyme of lung in 66-year-old male patient, and treated with surgical intervention. So we firstly reported it with review of literatures.

  • PDF

Overview of ALK and ROS1 Rearranged Lung Cancer

  • Choi, Chang Min
    • Tuberculosis and Respiratory Diseases
    • /
    • v.75 no.6
    • /
    • pp.236-237
    • /
    • 2013
  • Many attempts have been made to find genetic abnormalities inducing carcinogenesis after the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor targeting EGFR in lung cancer. New target therapies have been already commercialized and studied along with the recent discovery of gene rearrangement involved in the carcinogenic process of non-small cell lung cancer. This study aims to investigate anplastic lymphoma kinase, c-ros oncogene 1, and receptor tyrosine kinase, in particular.

Whole Brain Radiotherapy Plus Chemotherapy in the Treatment of Brain Metastases from Lung Cancer: A Meta-analysis of 19 Randomized Controlled Trails

  • Liu, Wen-Jing;Zeng, Xian-Tao;Qin, Hai-Feng;Gao, Hong-Jun;Bi, Wei-Jing;Liu, Xiao-Qing
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.7
    • /
    • pp.3253-3258
    • /
    • 2012
  • Objective: To evaluate the efficacy and safety of whole brain radiotherapy (WBRT) plus chemotherapy versus WBRT alone for treating brain metastases (BM) from lung cancer by performing a meta-analysis based on randomized controlled trials (RCTs). Methods: The PubMed, Embase, CENTRAL, ASCO, ESMO, CBM, CNKI, and VIP databases were searched for relevant RCTs performed between January 2000 and March 2012. After quality assessment and data extraction, the meta-analysis was performed using the RevMan 5.1 software, with funnel plot evaluation of publication bias. Results: 19 RCTs involving 1,343 patients were included. The meta-analyses demonstrated that compared to WBRT alone, WBRT plus chemotherapy was more effective with regard to the objective response rate (OR = 2.30, 95% CI = 1.79 - 2.98; P < 0.001); however, the incidences of gastrointestinal reactions (RR = 3.82, 95% CI = 2.33 - 6.28, P <0.001), bone marrow suppression (RR = 5.49, 95% CI = 3.65 - 8.25, P < 0.001), thrombocytopenia (RR = 5.83, 95% CI = 0.39 - 86.59; P = 0.20), leukopenia (RR = 3.13, 95% CI = 1.77 - 5.51; P < 0.001), and neutropenia (RR = 2.75, 95% CI = 1.61 - 4.68; P < 0.001) in patients treated with WBRT plus chemotherapy were higher than with WBRT alone. There was no obvious publication bias detected. Conclusion: WBRT plus chemotherapy can obviously improve total efficacy rate, butalso increases the incidence of adverse reactions compared to WBRT alone. From the limitations of this study, more large-scale, high-quality RCTs are suggested for further verification.

Sclerosing Hemangioma of the Lung - A case report - (폐에 발생한 경화성 혈관종)

  • 조은희
    • Journal of Chest Surgery
    • /
    • v.25 no.10
    • /
    • pp.1076-1081
    • /
    • 1992
  • The sclerosing hemangioma of the lung is rare, benign neoplasms, which are usually solitary, Althoughh their histologic apperances are distinct and well-defined, their histogenesis is uncertain. We experienced a typical lesion of pulmonary sclerosing hemangioma clinically and histologically, which was removed from the right lobe of 64-year-old female. We disccused histogenesis, microscopic feature and progress of the sclerosing hemangioma.

  • PDF

Reported Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis after Open Lung Biopsy (특발성 폐 섬유화증 환자에서 폐 생검후 발견된 폐 선암 치험 1예)

  • 최창우;허균;이재욱;원용순;고은석;신화균
    • Journal of Chest Surgery
    • /
    • v.37 no.12
    • /
    • pp.1032-1035
    • /
    • 2004
  • The specific diagnosis in diffuse interstitial lung disease may be obtained through open lung biopsy. Diffuse interstitial lung disease is often associated with lung cancer. We report one case of lung adenocarcinoma with idiopathic pulmonary fibrosis in whom previous open lung biopsy had been performed. We need general concepts about sites of open lung biopsy in these patients. Therefore, we report this case and document other references.

Epidemiology of Lung Cancer in Korea: Recent Trends

  • Park, Ji Young;Jang, Seung Hun
    • Tuberculosis and Respiratory Diseases
    • /
    • v.79 no.2
    • /
    • pp.58-69
    • /
    • 2016
  • Lung cancer causes the most cancer deaths in Korea. Although the smoking rate has begun to decrease, the prevalence of lung cancer is still increasing. We reviewed the national lung cancer registry data and the data published about lung cancer in Korea. In 2012, the crude incidence rate of lung cancer was 43.9 per 100,000. The age-standardized mortality rate of lung cancer was 19.8 per 100,000. The 5-year relative survival rate for lung cancer was 11.3% from 1993 to 1995 and increased to 21.9% in the period from 2008 to 2012. Lung cancer occurring in never-smokers was estimated to increase in Korea. Adenocarcinoma is steadily increasing in both women and men and has replaced squamous cell carcinoma as the most common type of lung cancer in Korea. In patients with adenocarcinoma, the frequency of EGFR mutations was 43% (range, 20%-56%), while that of the EMK4-ALK gene was less than 5%.